NCT06519955 Can PLIA Reduce Early Post-operative Pain After PAO Surgery?
| NCT ID | NCT06519955 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Michael C Willey |
| Condition | Hip Dysplasia |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-10-03 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 120 participants in total. It began in 2024-10-03 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to compare different peri-incisional local infiltrative anesthesia (PLIA) methods in patients ages 13 to 50 undergoing a periacetabular osteotomy (PAO). The main questions to answer here are: 1. Does PLIA impact post-operative pain after PAO? 2. Does PLIA impact pain medication usage as measured by morphine equivalent dosing (MED) after PAO? 3. Does the timing of PLIA administration impact post-operative pain and MED after PAO? Participants will be asked to complete some surveys; demographics survey, General Self-Efficacy Scale (GSE) and the Pain Resilience Scale. All other information will be gathered from the patients medical chart. Researchers will compare three groups. 1.) Patients who do not receive PLIA. 2.) Patients who receive PLIA after their incision is closed. 3.) Patients who receive PLIA throughout PAO.
Eligibility Criteria
Inclusion Criteria: * Adolescent or young adult diagnosed with hip dysplasia indicated for PAO at University of Iowa Hospital and Clinics. Exclusion Criteria: * Unable to provide informed consent. * Pregnant or breast-feeding individuals * Prisoner or ward of the state * Allergy or medical contradiction to any of the study medications * Patients undergoing femoral osteotomy or surgical hip dislocation with PAO will be excluded
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06519955 clinical trial?
This trial is open to participants of all sexes, aged 13 Years or older, up to 50 Years, studying Hip Dysplasia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06519955 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06519955 currently recruiting?
Yes, NCT06519955 is actively recruiting participants. Contact the research team at ashley-kochuyt@uiowa.edu for enrollment information.
Where is the NCT06519955 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06519955 clinical trial?
NCT06519955 is sponsored by Michael C Willey. The trial plans to enroll 120 participants.